http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012205581-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8c410e59c9fcb68baf2d34cdc6ab392 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2011-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6061cfd535c92cdff5a0a8c7ea03b236 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a537dae9d12d28604f35e28a35e7d616 |
| publicationDate | 2012-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2012205581-A |
| titleOfInvention | Method for producing non-MHC-restricted cytotoxic cells |
| abstract | PROBLEM TO BE SOLVED: To efficiently culture MHC non-restricted cytotoxic cells such as NK cells. SOLUTION: Peripheral blood mononuclear cells (PBMC) collected from humans such as cancer patients are treated with bisphosphonates such as IL-2, IL-18, zoledronate, TNF-α, and RetroNectin (registered trademark). In the presence of fibronectin, preferably IL-2 of 100 IU / ml to 4,000 IU / ml, IL-18 of 1 ng / ml to 500 ng / ml, bisphosphonate of 0.01 μM to 10 μM, 0.01 ng / ml or more The cells are cultured for 7 to 21 days in the presence of 500 ng / ml or less of TNF-α. The cultured cell population is administered to the collected patient and used as a cell preparation for cancer treatment. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2017094879-A1 |
| priorityDate | 2011-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 228.